Vitamin D Receptor Activators and Clinical Outcomes in Chronic Kidney Disease

Table 6

Mineral metabolism and bone disorder.

Author	Year	Study	Outcome
Slatopolsky et al. [31]	2003	A study in uremic rats to assess the efficacy of paricalcitol in prevention (protocol I) and treatment (protocol II) of hyperparathyroidism and renal osteodystrophy.	Paricalcitol was effective in preventing (protocol I) and suppressing (protocol II) the significant hyperparathyroidism induced by uremia and enhanced by a high phosphorus diet; it improved bone histology in uremic rats affected by severe secondary hyperparathyroidism.
Kazama et al. [32]	2005	𝑁=50 chronic dialysis patients with PTH levels >300 pg/mL treated with 10 μg of i.v. maxacalcitol thrice a week.	PTH, bone-specific alkaline phosphatase and osteocalcin levels were significantly lowered; serum calcium levels increased. Osteoprotegerin levels significantly decreased (𝑃<.0001).